Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ProAgio - ProDa BioTech

Drug Profile

ProAgio - ProDa BioTech

Alternative Names: ACT-50

Latest Information Update: 18 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Georgia State University
  • Developer Georgia State University; ProDa BioTech
  • Class Antineoplastics; Proteins
  • Mechanism of Action Integrin alphaVbeta3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pancreatic cancer; Solid tumours

Most Recent Events

  • 14 Jun 2024 ProDa Biotech plans a phase I/II trial for Triple-negative Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV, Injection) (NCT06460298)
  • 29 Dec 2023 ProDa BioTech in collaboration with Georgia State University and University of Alabama plans a phase I/Ib trial for Pancreatic cancer (Metastatic disease, Late-stage disease, Combination therapy, First-line therapy) (IV) (NCT06182072)
  • 11 Oct 2023 Efficacy, pharmacokinetics and adverse events data from phase I trial in Solid tumours and Pancreatic cancer were presented at the International Conference on Molecular Targets and Cancer Therapeutics ( AACR-NCI-EORTC 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top